期刊文献+

培美曲塞致药物不良反应文献分析 被引量:4

Document analysis on adverse drug reaction induced by pemetrexed
原文传递
导出
摘要 目的探讨培美曲塞致药品药物不良反应的规律和特点,为临床合理用药提供参考。方法检索2005年1月—2016年5月Pubmed数据库、中国期刊全文数据库(CNKI)、万方数字化期刊全文库、中文科技期刊全文数据库(维普)等数据库报道的培美曲塞致药物不良反应的文献,并进行分析和讨论。结果培美曲塞引起的药物不良反应共41例,男性明显多于女性,年龄集中在61~70岁;非小细胞肺癌发生的药物不良反应例数最多;用药4~6 d出现药物不良反应的例数最多,占39.0%;培美曲塞引发的药物不良反应以皮肤系统和消化系统损害较为常见,构成比分别为25.4%、23.1%。结论培美曲塞引发的药物不良反应较为常见,临床使用时应及时处理,以确保患者用药安全。 Objective To investigate the regularity and characteristics of adverse drug reaction(ADR) induced by pemetrexed, and to provide the references for the rational use of drugs in clinic. Methods ADR induced by pemetrexed in Pubmed Database, China Journal Full-text Database(CNKI), Wanfang Database, and Chinese Science and Technology Journal Full-text Database(VIP) from January 2005 to May 2016 were retrieved, and the literature involving cases were analyzed and discussed. Results A total of 41 cases reduced by pemetrexed were analyzed, in which men with ADR induced by pemetrexed were more than those of women, and the ages of patients were mainly 61 — 70 years old. Patients with non-small cell lung cancer had the most ADR cases. The most cases(39.0%) were found in the medication during 4 — 6 days. ADR induced by pemetrexed mainly were skin system(25.4%) and digestive system(23.1%). Conclusion ADR induced by pemetrexed is common in clinic. The using of pemetrexed should be treated promptly to ensure the medication safety.
出处 《现代药物与临床》 CAS 2016年第11期1842-1845,共4页 Drugs & Clinic
基金 天津市卫生局科技基金面上项目(2014KY05)
关键词 培美曲塞 药物不良反应 文献分析 pemetrexed adverse drug reaction document analysis
  • 相关文献

参考文献7

二级参考文献35

  • 1陈治宇,许立功.抗肿瘤新药——培美曲塞[J].中国新药与临床杂志,2005,24(2):143-147. 被引量:58
  • 2曹国颖,徐巧玲,傅得兴.多靶点抗肿瘤药物——培美曲塞二钠[J].药物不良反应杂志,2006,8(2):148-151. 被引量:20
  • 3马飞,李树婷,孙燕.2006年培美曲塞研究新进展[J].癌症进展,2006,4(6):523-528. 被引量:16
  • 4潘雁,朱珺.培美曲塞致肾功能不全、消化道出血[J].药物不良反应杂志,2007,9(2):94-94. 被引量:8
  • 5杨剑霞.晚期非小细胞肺癌患者培美曲塞化疗的护理[J].护理学报,2007,14(2):78-79. 被引量:7
  • 6Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta) [ J ]. Oncologist, 2004, 9(5) :482-488.
  • 7Mita AC, Sweeney C J, Baker SD, et al. Phase Ⅰ and pharmcokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function [ J ]. J Clin Oncol, 2006, 24 (18S) :7093a.
  • 8EISENHAUER E A, THERASSEB P, BOGAERTSC J, et al. New respongse evaluation criteria in solid tumours: revised RECIST guideline( version 1. 1) [ J ] . Eur J Cancer, 2009, 45(2): 228-247.
  • 9AL-SALEH K, QUINTON C, LLLIS P M. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized con-trolled trials, with histology subgroup analysis [ J ]. Curt Oncol, 2012,19(1): 9-15.
  • 10HANNA N, SHEPHERD F A, FOSSELLA F V, et al. Randomized phase II trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer preViously treated with chemotherapy [ J ] . J Clin Oncol, 2004, 22 (9): 1589- 1597.

共引文献33

同被引文献24

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部